TPIV-200 is under clinical development by Marker Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TPIV-200’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 21 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TPIV-200 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TPIV-200 overview

TPIV-200 is under development for the treatment of triple negative breast. The vaccine candidate is administered intradermally. TPIV-200 is a lyophilized/freeze dried cancer vaccine comprising of unique peptide epitopes targeting folate receptor alpha in both breast cancer and ovarian cancer. The vaccine candidate is based on TAP expression technology. It was under development for epithelial ovarian cancers, endometrial cancer, peritoneal cancer, platinum sensitive ovarian cancer and fallopian tube cancer.

Marker Therapeutics overview

Marker Therapeutics is a clinical-stage immuno-oncology company that carries out the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company’s pipeline products include MT-401, which is used for the treatment of post-transplant AML and MT-601, which is used for the treatment of advanced unresectable pancreatic cancer. It also provides Multi-Antigen Targeted (MultiTAA) technology that utilizes a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood. Marker Therapeutics carries out several clinical studies including acute myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma and breast cancer. Marker Therapeutics is headquartered in Houston, Texas, the US.

Quick View TPIV-200 LOA Data

Report Segments
  • Innovator
Drug Name
  • TPIV-200
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.